Momenta Pharmaceuticals, Inc. (MNTA) Financial Statements (2024 and earlier)

Company Profile

Business Address 301 BINNEY STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2020
MRQ
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 545,110449,411379,890353,151350,044191,529
Cash and cash equivalents 382,515248,33473,651150,73861,461 
Short-term investments 139,129174,076269,017202,413288,583130,180
Other undisclosed cash, cash equivalents, and short-term investments 23,46627,00137,222  61,349
Restricted cash and investments   2,412   
Receivables 8,01311,37115,04870,24219,3857,427
Other undisclosed current assets (13,996)(19,359)(30,424)4,6075,2796,374
Total current assets: 539,127441,423366,926428,000374,708205,330
Noncurrent Assets
Property, plant and equipment 11,49920,94429,91620,84721,89625,422
Long-term investments and receivables 23,46627,00137,222   
Long-term investments 23,46627,00137,222   
Intangible assets, net (including goodwill) 1,7302,8834,0365,1893,5284,589
Intangible assets, net (excluding goodwill) 1,7302,8834,0365,1893,5284,589
Restricted cash and investments 1,84937,89820,62021,76120,66020,719
Other noncurrent assets 40,6941,4147111,940248156
Total noncurrent assets: 79,23890,14092,50549,73746,33250,886
TOTAL ASSETS: 618,365531,563459,431477,737421,040256,216
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 72,93923,41231,98430,49828,55224,693
Employee-related liabilities      6,912
Accounts payable 14,1409,35211,4563,6324,0537,433
Accrued liabilities 58,79914,06020,52826,86624,49910,348
Deferred revenue 895
Restructuring reserve 343,235    
Other liabilities 28,11316,22737911460518
Deferred revenue and credits2,8667,2729,7705,490
Contract with customer, liability3,916
Other undisclosed current liabilities 4,1234,7219,25832,895 (6,912)
Total current liabilities: 106,10451,51144,48770,67638,78223,789
Noncurrent Liabilities
Liabilities, other than long-term debt 57,80119,04440,79035,15312,28226,059
Deferred revenue and credits30,75131,36012,21325,508
Deferred revenue 940
Contract with customer, liability1,774
Other liabilities 56,86117,27010,0393,79369551
Total noncurrent liabilities: 57,80119,04440,79035,15312,28226,059
Total liabilities: 163,90570,55585,277105,82951,06449,848
Equity
Equity, attributable to parent 454,460461,008374,154371,908369,976206,368
Common stock 12108775
Treasury stock, value (3,114)(3,114)(3,114)(3,114)(2,048) 
Additional paid in capital 1,491,1471,208,025939,654848,304824,385575,438
Accumulated other comprehensive income (loss) 296(87)(140)864(16)
Accumulated deficit (1,033,881)(743,826)(562,254)(473,375)(452,372)(369,059)
Total equity: 454,460461,008374,154371,908369,976206,368
TOTAL LIABILITIES AND EQUITY: 618,365531,563459,431477,737421,040256,216

Income Statement (P&L) ($ in thousands)

6/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 23,86875,589138,882109,61989,65052,250
Revenue, net138,882109,61989,65052,250
Gross profit: 23,86875,589138,882109,61989,65052,250
Operating expenses (321,959)(256,916)(231,433)(184,346)(174,084)(151,646)
Operating loss: (298,091)(181,327)(92,551)(74,727)(84,434)(99,396)
Nonoperating income 8,0365,2664,45553,7241,121796
Investment income, nonoperating 9,2066,1944,4272,226808548
Other nonoperating income (expense) 848(928)2851,498313248
Interest and debt expense (2,018)     
Loss from continuing operations: (292,073)(176,061)(88,096)(21,003)(83,313)(98,600)
Loss before gain (loss) on sale of properties: (292,073)(176,061)(88,096)(21,003)(83,313)(98,600)
Net loss attributable to parent: (292,073)(176,061)(88,096)(21,003)(83,313)(98,600)
Other undisclosed net income available to common stockholders, basic 2,018     
Net loss available to common stockholders, diluted: (290,055)(176,061)(88,096)(21,003)(83,313)(98,600)

Comprehensive Income ($ in thousands)

6/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (292,073)(176,061)(88,096)(21,003)(83,313)(98,600)
Comprehensive loss: (292,073)(176,061)(88,096)(21,003)(83,313)(98,600)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 2,40153(226)8220(41)
Comprehensive loss, net of tax, attributable to parent: (289,672)(176,008)(88,322)(20,921)(83,293)(98,641)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: